Q-omics provides the consensus-scored SOCS3 profile across patient tissues and cancer cell-line models. SOCS3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SOCS3 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, SOCS3 RNA expression shows 19,536 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KICH, and GBM as cancer lineages where SOCS3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SOCS3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SOCS3 survival associations across molecular data types. SOCS3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SOCS3 RNA expression–survival associations across cancer types. High SOCS3 expression shows unfavorable associations in ACC, KIRC, UVM, KIRP, LGG and STAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SOCS3 RNA expression.
This table summarizes SOCS3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SOCS3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SOCS3 shows lower tumor expression in KICH, BLCA, BRCA, LUSC, LIHC and LUAD. The KICH box plot shows higher SOCS3 RNA expression in normal versus tumor tissue (log2 FC = −4.044, t-test p < 0.001).
This table shows molecular features associated with SOCS3 in patient tissues and cancer cell lines. In patient samples, SOCS3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SOCS3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
